Department of Laboratory Haematology, Royal Melbourne Hospital, Vic., Australia.
Br J Haematol. 2010 Jun;149(5):768-74. doi: 10.1111/j.1365-2141.2010.08150.x. Epub 2010 Mar 21.
Thirteen adult patients aged 22-63 (median 30) years with sickle cell disease (SCD) were enrolled in a regular erythrocytapheresis (ECP) programme at a single institution between December 1998 and November 2008. The indications for enrolment were recurrent painful crises (PC), acute chest syndrome (ACS), silent cortical ischaemia, pulmonary hypertension, multi-organ crises and pregnancy. Endpoints retrospectively evaluated included the incidence of SCD-related acute events requiring hospitalization following and prior to regular ECP, the development of new and progression of pre-existing related end-organ damage, the effectiveness in reducing HbS levels acutely and prior to the next exchange and the transfusion-related complications. Sixteen acute sickle-related events occurred in five patients in 846 months of patient follow-up. In all patients with reliable data available pre-ECP, the frequency of such events was reduced following commencing regular ECP. No patient experienced stroke, multi-organ crises or developed new and/or progression of end-organ dysfunction. Regular ECP reduced HbS levels to the target of <30% immediately post-exchange. Alloimmunization rates were comparable to the literature and ECP was effective in preventing progressive iron overload. Regular ECP was demonstrated to be an effective, well-tolerated therapy for both acute and chronic complications of SCD in adults.
1998 年 12 月至 2008 年 11 月期间,在一家单家机构中,对 13 名年龄在 22-63 岁(中位数 30 岁)的患有镰状细胞病(SCD)的成年患者进行了常规红细胞分离术(ECP)治疗。入组的指征为反复发作的疼痛性危象(PC)、急性胸部综合征(ACS)、无症状皮质缺血、肺动脉高压、多器官危象和妊娠。回顾性评估的终点包括:接受常规 ECP 前后与 SCD 相关的急性事件的发生率,需要住院治疗;新发病和已存在的相关终末器官损害的进展;在下次置换前急性降低 HbS 水平的有效性;以及输血相关并发症。在 846 个月的患者随访中,有 5 名患者的 16 次急性镰状细胞相关事件。在所有可获得 ECP 前可靠数据的患者中,在开始常规 ECP 后,此类事件的发生频率降低。没有患者发生中风、多器官危象或出现新的和/或进展性终末器官功能障碍。定期 ECP 将 HbS 水平迅速降低到<30%的目标值。同种免疫发生率与文献相似,ECP 可有效预防铁过载的进展。定期 ECP 被证明是一种有效的、耐受性良好的治疗方法,可用于治疗成人 SCD 的急性和慢性并发症。